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Abstract
Inflammatory bowel disease is associated with an increased likelihood of developing lymphoma. However, it is still con-
troversial if this risk may be attributed to the disease itself or rather represents an effect of immunosuppressive treatment. 
Although tumor necrosis factor alpha (TNFα) is a key cytokine for cancer immunosurveillance, the potential relationship 
between anti-TNFα agents and the pathogenesis of lymphoproliferative disorders remains unclear. Here, we describe the 
case of a patient with severe perianal Crohn’s disease, treated with infliximab monotherapy, whose unusual presentation 
with acute groin pain required surgical intervention and led to the diagnosis of diffuse large B-cell lymphoma. However, 10 
months after this episode, treatment with infliximab was restarted because the patient continued with refractory and disa-
bling perianal disease. Currently, with a follow-up of 36 months, under infliximab 10 mg/kg every 4 weeks, he maintains 
mild perianal Crohn’s disease and persists in sustained clinical and imaging remission of the lymphoproliferative disorder.
Keywords Lymphoma · Lymphoproliferative disorder · Crohn’s disease · Inflammatory bowel disease · Infliximab · Anti-
TNFα
Introduction
Tumor necrosis factor alpha (TNFα), a key mediator of 
inflammation, plays a crucial role in the pathogenesis of 
inflammatory bowel disease (IBD) [1]. In fact, TNFα antag-
onists have become widely used and have shifted the para-
digm in the management of IBD over the past few years [2, 
3]. Notwithstanding, TNFα is also critical for cancer immu-
nosurveillance and defense against infections [4, 5]; thus, 
concerns have been raised regarding the use of anti-TNFα 
therapy and the risk of certain complications, including 
lymphoma [6]. Crohn’s disease patients have been associ-
ated with an increased risk of lymphoproliferative disorders, 
especially non-Hodgkin lymphoma [7]; however, it remains 
controversial whether this only represents a causal effect of 
immunosuppressive therapy or if IBD itself is an independ-
ent risk factor for lymphoma [8]. Although subjects with 
intestinal lymphomas may experience bowel complications 
requiring surgery, acute groin pain as the first presentation 
of a nodal lymphoma is extremely unlikely and has not been 
described before in an IBD patient. We present the case of 
a Crohn’s disease patient, under treatment with infliximab, 
who was diagnosed with a nodal lymphoma after presenting 
with acute groin pain.
Clinical case
A 29-year-old male, with a history of recurrent perianal fis-
tulas and abscesses, who maintained severe anal pain and 
perianal purulent drainage despite several surgical proce-
dures, was referred to our center. A proctological exami-
nation under anesthesia revealed a deep ulcer in the anal 
canal and perianal abscess, for which incision, drainage, 
and seton placement were performed and antibiotics were 
administered. He underwent a colonoscopy that showed skip 
areas with decreased vascular pattern and ulceration in all 
colon segments and in the terminal ileum, and biopsies were 
taken. Histopathological analysis findings and further pelvic 
magnetic resonance (MR) imaging and MR enterography 
allowed the diagnosis of ileocolonic and complex perianal 
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Crohn’s disease. The patient was started on treatment with 
prednisolone (50 mg daily) and, given the extent and severity 
of the luminal and perianal involvement, a top-down strategy 
was adopted—infliximab 5 mg/kg was initiated (at 0, 2 and 
6 weeks, and thereafter every 8 weeks) shortly after ster-
oid initiation. In the following months, since he maintained 
complex and disabling perianal disease and having required 
several surgical procedures to unroof the fistula tracts and 
seton placement, infliximab dose adjustment (by shortening 
the infusion intervals to every 6 weeks) and its combination 
with hyperbaric oxygen therapy were required.
In July 2014, 17 months after anti-TNFα initiation and 
while in clinical remission of luminal Crohn’s disease, the 
patient presented to the emergency department with a 5-h 
history of severe pain and swelling in the right inguinal 
region. Upon examination, a painful bulky and non-reducible 
mass was found, leading to the clinical diagnosis of incar-
cerated right inguinal hernia, for which he underwent sur-
gery. However, surgical exploration unexpectedly revealed a 
highly vascularized 5-cm lymph node with a necrotic center, 
without any evidence of inguinal hernia. Regional lymphad-
enectomy was performed and resected specimens were sent 
for histological and microbiological evaluation. Apart from 
a slight increase in C-reactive protein (24 mg/L), initial labo-
ratory studies, which also included complete blood count, 
erythrocyte sedimentation rate, renal and liver function tests, 
lactate dehydrogenase, creatine kinase and Epstein–Barr 
virus serologies, were unremarkable. Further histological 
analysis of the enlarged lymph node described the presence 
of architectural distortion and diffuse infiltration of large 
atypical lymphocytes, with irregular nuclei, some of which 
with visible nucleoli (Fig. 1). The immunohistochemistry 
profile (CD20+, CD3−, Bcl-6+, CD10−, MUM-1−, Bcl-
2−) was compatible with diffuse large B-cell lymphoma of 
germinal center B-cell-like subtype (Fig. 2). The remaining 
resected lymph nodes did not show histological features of 
malignancy. Additional investigation included bone marrow 
biopsy, full body computed tomography (CT) scan, positron 
emission tomography-CT and measurement of beta-2-mi-
croglobulin, which were all normal. The post-procedure 
course was uneventful and he was discharged being com-
pletely asymptomatic. A multidisciplinary approach was 
undertaken which included representatives from the hema-
tology team who advised that chemotherapy in a patient with 
persistent perianal suppuration could result in an extremely 
high risk of infectious complications. Therefore, given his 
staging (Ann Arbor stage I) and clinical features and the 
involvement of a single lymph node, it was decided not to 
perform chemotherapy. Anti-TNFα therapy was suspended 
and the patient was kept under observation and close moni-
toring. In the following months, he developed recurrent 
perianal supuration despite antibiotics, topical treatment 
and hyperbaric oxygen therapy. Approximately 10 months 
later, since he continued with severe and disabling perianal 
Fig. 1  a, b Lymph node revealing diffuse infiltration of large atypical cells, with irregular nuclei and visible nucleoli (H&E stain; a ×100, b 
×400)
Fig. 2  Immunohistochemistry staining for Bcl-2 (×200)
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involvement, the difficult decision of restarting infliximab 
therapy was taken, after discussion with the hematology 
team and careful consideration of the risks and benefits. 
Currently, with a follow-up of 36 months, under infliximab 
10 mg/kg every 4 weeks, he maintains mild perianal Crohn’s 
disease and persists in sustained clinical and imaging remis-
sion of the lymphoma (Fig. 3).
Discussion
In the Western world, there has been an upward trend in 
the incidence of lymphoma in the past few decades, along 
with a parallel increase in the occurrence of inflammatory 
conditions treated with immunosuppressive agents [9]. Vari-
ous studies have identified an increased risk of lymphoma 
among patients with several chronic inflammatory disorders 
[10, 11]. Persistent activation of the immune system may 
exert a critical influence in the genesis of lymphoprolifera-
tive disorders; chronic B-cell stimulation and proliferation, 
in particular, appear to pose a significant threat [12]. With 
regard to IBD, some controversy still exists concerning the 
contribution of this disease to the occurrence of hematologi-
cal malignancies. Although large population-based studies 
did not show a correlation between IBD and such conditions, 
a meta-analysis conducted by Pedersen et al. suggested that 
Crohn’s disease patients would have a borderline signifi-
cant increase in the likelihood of developing a lymphoma 
[13–15]. These latter results were corroborated by a sub-
sequent population-based study which revealed an associa-
tion between Crohn’s disease and non-Hodgkin lymphoma, 
unrelated to thiopurine exposure [7]. Additionally, advanced 
age, male gender, genetic mutations, certain viral infections 
and, most importantly, immunosuppressive therapy, were 
identified as risk factors for developing lymphoprolifera-
tive disorders in IBD patients [8]. In fact, despite remain-
ing uncertainties regarding the potential independent role of 
the disease itself in the pathogenesis of those disturbances, 
the contribution of immunosuppressive therapy is widely 
known. Patients treated with thiopurines were shown to have 
a 4- to 5-fold increase in the risk of acquiring lymphoma, 
with this risk being correlated with the duration of treatment 
and being eliminated after its cessation [16, 17]. Regard-
ing anti-TNFα therapy, apart from the case of hepatosplenic 
T-cell lymphoma, for which they seem to potentiate the del-
eterious effect of thiopurines, there is not enough evidence 
to claim that these agents may contribute to lymphoma 
occurrence [8]. Both a systematic review of registries and 
prospective observational studies of rheumatoid arthritis 
patients and an analysis of the Crohn’s Therapy, Resource, 
Evaluation and Assessment Tool (TREAT) registry did not 
verify a higher probability of such complications among 
Fig. 3  Clinical course of the patient [PDAI perianal disease activity index, C-reactive protein (mg/dL) and treatment (IFX infliximab)]
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subjects who underwent anti-TNFα treatment [18, 19]. Thus, 
in a patient like ours, who was submitted only to anti-TNFα 
therapy and has never been exposed to thiopurines, the pos-
sible association between treatment and these malignancies 
is even more doubtful.
Diffuse large B-cell lymphoma (DLBCL) accounts for 
approximately one-third of adult non-Hodgkin lymphoma 
cases and usually presents with palpable lymphadenopathies 
or extranodal involvement [20, 21]. Since the gastrointestinal 
tract is a frequent extranodal site of involvement in non-
Hodgkin lymphomas (the most common in DLBCL), diag-
nosis often occurs following surgery for any abdominal com-
plication, such as intussusception, acute appendicitis, bowel 
perforation, obstruction or even ischemia due to mesenteric 
thrombosis [22–26]. Although DLBCL frequently shows a 
rapid proliferation rate, it is surprising that this phenom-
enon could be sufficient to manifest itself as an acute phe-
nomenom, such as in our patient, whose initial presentation 
with an extremely painful bulky and non-reducible mass, 
which started only a few hours before admission, simulated 
an incarcerated inguinal hernia and led to surgery.
Several authors have reported spontaneous regression 
of lymphoma after immunosuppressive therapy withdrawal 
[27–31]. Nonetheless, we did not find any case in the lit-
erature of anti-TNFα resumption in this setting. The avail-
able evidence is still insufficient to warrant the safety of 
such drugs in patients with a background of hematological 
malignancy. However, in a patient like ours, with persistently 
active and severely disabling perianal Crohn’s disease, the 
difficult decision to reinitiate biological therapy has ensured 
clinical improvement without relapse of the lymphoprolif-
erative disorder during the follow-up period.
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